Docetaxel demonstrates stronger safety and survival profile than cabazitaxel for prostate cancer

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.